Interaction of estradiol and vitamin D with low skeletal muscle mass among middle-aged and elderly women

Muscle atrophy is a physiological phenomenon associated with aging, characterized by a normal decline in muscle mass and function, known as sarcopenia, which is manifested in a decrease in skeletal muscle mass, muscle strength, and physical activity, and often coexists with obesity [1, 2]. Sarcopenia can further deteriorate the musculoskeletal health of the elderly by raising the risk of osteoporotic vertebral and hip fractures [3], which ultimately results in mobility restrictions, functional impairment, physical disability, and even a lower quality of life [4]. Sarcopenia not only effects very elderly individuals, but can also be widely observed in middle-aged adults [5]. Sarcopenia currently affects more than 50 million people, and by 2050, it is predicted that number will rise to more than 200 million [1]. Studies have found that skeletal muscle declines substantially from about 30 years old, with an annual loss rate of approximately 0.1–0.5%, while the rate acceleration dramatically post age 65 [6].

The reduction of skeletal muscle mass is not only linked to negative social and financial effects like hospitalization and mortality [7], also connected to comparable gender-neutral alterations, such as heightened inflammation, satellite cell senescence, decreased protein synthesis, and myocyte regeneration [8], as well as some additional gender-specific alterations brought on by a decrease in sex hormones with aging [9]. Furthermore, according to a number of studies, women have physiologically lower levels of skeletal muscle mass than men, which frequently results in sarcopenia [10, 11]. The onset of female sarcopenia appears to be more susceptible to menopause, which may be the cause of this difference between men and women [12].

Menopause is a physiological age-related condition in women that is accompanied by a drop in hormone levels, especially estradiol levels [13, 14]. Estradiol is essential for both female growth and aging, maintaining the sexual characteristics of female. Meanwhile, estradiol can also promote muscle regeneration and contribute to muscle health [1, 15]. Nevertheless, reduction of estradiol during menopause can results in musculoskeletal discomfort [16], resulting in modifications to body composition including skeletal muscle loss and fat accumulation, and even raise the danger of vitamin D deficiency, which might aggravate musculoskeletal discomfort conversely [17]. According to previous studies, the estrogen can stimulate vitamin D metabolism in postmenopausal women by increasing 1,25(OH)₂ D levels, which could potentially explain the mechanism behind the interaction between vitamin D deficiency and estrogen regarding low skeletal muscle mass [18, 19].

Indeed, vitamin D deficiency poses a significant health challenge worldwide, especially the elderly. Numerous studies have linked a vitamin D deficiency to skeletal muscle loss and reduction in physical function [20, 21], compromising the strength of muscle in the lower limbs [22], whereas others have indicated that vitamin D has no effect on boosting muscle mass or only a weak correlation with muscle atrophy [23]. Therefore, given the association of vitamin D deficiency and muscle atrophy is still controversial, and estradiol not only plays a key role during women’s menopause but have an effect on muscle atrophy simultaneously. This study was thus conducted to determine whether low skeletal muscle mass in middle-aged and elderly women was affected by estradiol and vitamin D levels together, which may serve as an useful theoretical foundation for future combination of vitamin D and estradiol supplementation therapies.

The primary objective of this study was to determine whether concentrations of vitamin D and estradiol were related to low SMM among middle-aged and elderly women. Our study revealed a negative correlation between low skeletal muscle mass and levels of vitamin D and estradiol. However, when considered confounding factors, including age, residence, marital status, educational level, smoking and drinking status, physical activity, BMI, FM, triglyceride, menopausal status, and dietary energy, these correlations were maintained in estradiol Q1, Q2, Q3 and vitamin D Q1. Furthermore, we evaluated whether there was any combined association of estradiol and vitamin D levels on low SMM. In this respects, we found that participants with the lower quartile of estradiol concentrations and vitamin D deficiency had a higher likelihood of developing low skeletal muscle, compared to those in the highest quartile of estradiol concentrations and non-vitamin D deficiency. Considering the applicability of the definition of vitamin D deficiency in the population, we further used the quartile of vitamin D to explore the interaction between vitamin D and estradiol on low SMM, obtaining similar results.

To our knowledge, not only is the connection between muscle atrophy and vitamin D and estradiol status ambiguous, but also these combined effects on muscle atrophy have not been studied. This study is the first study evaluating the combined association of estradiol and vitamin D levels on low SMM among middle-aged and elderly women. Previous studies have found that the muscle atrophy onset is multifactorial and determined by several promoting factors [32, 33]. Menopause seems to be particularly closely correlated with the beginning of muscle atrophy in women, which brings about hormone changes, especially estradiol [34]. Besides, muscle atrophy may also be triggered by vitamin D [35].

While estradiol levels change throughout life, the majority of women experience the menopausal transition in their mid-40s, a period of time during which the level of female hormones decreases and the menstrual cycle becomes irregular. In fact, estradiol is crucial for preserving muscle health in older people [36]. Previous researches have shown a close relationship between estradiol concentrations decrease and muscle atrophy [37, 38], which is in line with the findings of this investigation. However, controversial results have been reported, indicating that estradiol has no impact on postmenopausal women’s muscle atrophy [39]. Despite all this, several basic experimental studies have confirmed that interleukin (IL)-6, IL-1, and tumor necrosis factor-a (TNF-α) production are all closely associated with menopause [40]. Meanwhile, the IL-6 and TNF-α can impair muscle performance [41, 42], causing sarcopenia [43, 44].

Additionally, vitamin D, a vital hormone linked to muscle physiology, appears to be involved in muscle atrophy [45]. According to prior researches, low muscle strength and physical performance of elderly adults are associated with their low vitamin D concentration [46‐49]. Meanwhile, other studies also revealed that older adults with vitamin D deficiency are more likely to develop muscle mass and muscle strength decline [50, 51]. These outcomes are consistent with those from our study, which demonstrated a significant relationship between low vitamin D concentrations and low skeletal muscle mass in relation to recent muscle atrophy. Given the lack of clearly defined mechanisms, the genomic pathway using the nuclear receptor VDR [52] and the non-genomic pathway, where vitamin D enters and affects cells directly through the cell surface fossa [53], are the potential mechanisms. Myofibres and numerous other cell types combine to form the mature skeletal muscle, which also contains vitamin D target cells [54]. As a result, vitamin D may interact intricately with the different skeletal muscle cells and tissues to affect muscle mass and performance [35].

In this study, low concentrations of vitamin D and estradiol have combined effect on muscle atrophy. Estradiol is known to decrease among the menopausal transition and vitamin D deficiency occur at lots of countries worldwide [55]. According to prior research, the relationship between vitamin D and estradiol in female populations remains inconclusive. Some studies have found a significant negative correlation between 25(OH) D and estrogen in fertile women [56], while similar findings were observed in postmenopausal women [57]. On the other hand, other studies have reported a positive correlation between vitamin D and estradiol [58], suggesting that their relationship may be influenced by multiple factors and may involve mutual regulation. Meanwhile, the hormone as a crucial element throughout life and decrease with aging, especially in muscle atrophy development. Notably, other evidences suggested that the hormone replacement therapy is good for muscle mass and strength in postmenopausal women [59, 60]. Nutritional and lifestyle factors may not only benefit muscle mass and performance, but also affordable and secure. However, despite the fact that a lot of research has been done in the past on supplement therapy, more research is required to evaluate the effectiveness and long-term safety of potential therapeutic interventions aimed at improving muscle function.

The present study has several benefits, including the fact that potential confounding factors like socioeconomic status, lifestyle, and macronutrients were taken into account when conducting the analyses. Moreover, from a dietary and nutritional perspective, it should also be pointed out that our research design and analysis methodology can effectively prevented confounding changes in overall macronutrient balance and dietary intake. Simultaneously, in contrast to prior research, this study also explored the impact of low skeletal muscle mass in middle-aged and elderly women, examining the interaction between estradiol and vitamin D. However, constraints on the current study should be taken into account. First, instead of dual-energy X-ray absorptiometry, which is the gold standard method for determining human body composition, BIA was employed because it is a reliable and useful method [61]. Second, we have to emphasize that a relatively small sample of rural women were included in this research, so the more in-depth research is still needed.

In conclusion, vitamin D deficiency is common among middle-aged and elderly women, and estradiol declines during the menopausal transition, both of which have important fundamental biological effects and interactions on muscle mass and performance. We conclude the vitamin D and estradiol were interactively correlated with low skeletal muscle mass in middle-aged and elderly women. Therefore, the combination of estradiol and vitamin D supplements should be encouraged for middle-aged and elderly women who are at risk of muscle atrophy or experiencing muscle atrophy.